Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Venous Thromboembolism | 19 | 2024 | 1822 | 3.340 |
Why?
|
Antithrombin III Deficiency | 4 | 2024 | 28 | 2.850 |
Why?
|
Antithrombin III | 6 | 2024 | 129 | 2.670 |
Why?
|
Thrombophilia | 4 | 2023 | 304 | 2.270 |
Why?
|
Hemophilia A | 6 | 2022 | 359 | 2.240 |
Why?
|
Anticoagulants | 18 | 2024 | 4831 | 1.750 |
Why?
|
Hemostasis | 4 | 2023 | 458 | 1.530 |
Why?
|
Heparin | 4 | 2021 | 1645 | 1.490 |
Why?
|
Hemostatics | 3 | 2022 | 239 | 1.440 |
Why?
|
Frameshift Mutation | 2 | 2024 | 388 | 1.440 |
Why?
|
Upper Extremity Deep Vein Thrombosis | 2 | 2021 | 26 | 1.430 |
Why?
|
Fibrinogens, Abnormal | 2 | 2020 | 10 | 1.430 |
Why?
|
Afibrinogenemia | 2 | 2020 | 18 | 1.430 |
Why?
|
Postthrombotic Syndrome | 3 | 2014 | 28 | 1.350 |
Why?
|
Anemia, Sickle Cell | 5 | 2022 | 1055 | 1.330 |
Why?
|
Venous Thrombosis | 8 | 2020 | 1278 | 1.260 |
Why?
|
Drug Monitoring | 4 | 2021 | 958 | 1.260 |
Why?
|
Blood Coagulation Disorders | 2 | 2023 | 346 | 1.210 |
Why?
|
Heterozygote | 2 | 2024 | 2785 | 0.980 |
Why?
|
Hemorrhage | 8 | 2021 | 3568 | 0.980 |
Why?
|
Thrombolytic Therapy | 4 | 2021 | 2096 | 0.880 |
Why?
|
Hemophilia B | 2 | 2016 | 83 | 0.870 |
Why?
|
Deamino Arginine Vasopressin | 1 | 2022 | 88 | 0.830 |
Why?
|
Thrombosis | 4 | 2023 | 3018 | 0.790 |
Why?
|
Blood Coagulation | 5 | 2022 | 1149 | 0.780 |
Why?
|
22q11 Deletion Syndrome | 1 | 2021 | 17 | 0.760 |
Why?
|
Partial Thromboplastin Time | 2 | 2019 | 205 | 0.720 |
Why?
|
Thoracic Outlet Syndrome | 1 | 2021 | 91 | 0.700 |
Why?
|
Catheterization, Swan-Ganz | 1 | 2019 | 86 | 0.670 |
Why?
|
Cytapheresis | 1 | 2018 | 8 | 0.660 |
Why?
|
Klinefelter Syndrome | 1 | 2018 | 47 | 0.610 |
Why?
|
Adolescent | 35 | 2022 | 86766 | 0.600 |
Why?
|
Pulmonary Embolism | 4 | 2021 | 2515 | 0.600 |
Why?
|
Vena Cava, Inferior | 2 | 2018 | 456 | 0.600 |
Why?
|
Exercise Therapy | 2 | 2022 | 907 | 0.590 |
Why?
|
Mesenteric Arteries | 1 | 2018 | 177 | 0.590 |
Why?
|
Factor Xa | 2 | 2019 | 166 | 0.590 |
Why?
|
Popliteal Artery | 1 | 2019 | 312 | 0.580 |
Why?
|
Fibrinogen | 1 | 2020 | 884 | 0.570 |
Why?
|
Nomograms | 1 | 2019 | 238 | 0.570 |
Why?
|
Thrombocytopenia | 2 | 2016 | 1170 | 0.560 |
Why?
|
von Willebrand Disease, Type 3 | 2 | 2013 | 5 | 0.550 |
Why?
|
Child, Preschool | 23 | 2021 | 41660 | 0.550 |
Why?
|
von Willebrand Disease, Type 2 | 1 | 2016 | 7 | 0.550 |
Why?
|
Child | 34 | 2024 | 79004 | 0.550 |
Why?
|
Valproic Acid | 1 | 2019 | 444 | 0.540 |
Why?
|
Arterial Occlusive Diseases | 1 | 2019 | 756 | 0.500 |
Why?
|
Antithrombin Proteins | 1 | 2014 | 10 | 0.480 |
Why?
|
Angioplasty, Balloon | 1 | 2018 | 610 | 0.480 |
Why?
|
Decision Support Systems, Clinical | 1 | 2024 | 1150 | 0.470 |
Why?
|
Lower Extremity | 2 | 2019 | 1183 | 0.470 |
Why?
|
Thromboembolism | 1 | 2021 | 997 | 0.460 |
Why?
|
Infant | 20 | 2021 | 35675 | 0.460 |
Why?
|
Point Mutation | 1 | 2019 | 1591 | 0.450 |
Why?
|
Fibrinolytic Agents | 2 | 2023 | 2167 | 0.450 |
Why?
|
Blood Coagulation Factors | 1 | 2016 | 355 | 0.450 |
Why?
|
Decompression, Surgical | 1 | 2018 | 595 | 0.450 |
Why?
|
Central Nervous System Neoplasms | 1 | 2020 | 905 | 0.410 |
Why?
|
von Willebrand Diseases | 1 | 2013 | 131 | 0.400 |
Why?
|
Orthopedic Procedures | 1 | 2021 | 1252 | 0.390 |
Why?
|
Dermatofibrosarcoma | 1 | 2011 | 47 | 0.390 |
Why?
|
Sinus Thrombosis, Intracranial | 1 | 2012 | 110 | 0.380 |
Why?
|
Factor VIII | 4 | 2022 | 349 | 0.380 |
Why?
|
Databases, Factual | 3 | 2023 | 7897 | 0.370 |
Why?
|
Sports | 2 | 2016 | 690 | 0.370 |
Why?
|
Ischemia | 1 | 2019 | 1875 | 0.370 |
Why?
|
Body Weight | 2 | 2021 | 4605 | 0.370 |
Why?
|
Histiocytic Sarcoma | 1 | 2011 | 40 | 0.370 |
Why?
|
Infant, Newborn | 11 | 2022 | 25919 | 0.360 |
Why?
|
Genes, p16 | 1 | 2011 | 158 | 0.360 |
Why?
|
Acute Chest Syndrome | 1 | 2010 | 31 | 0.350 |
Why?
|
Humans | 63 | 2024 | 752411 | 0.340 |
Why?
|
Young Adult | 17 | 2022 | 57632 | 0.340 |
Why?
|
Anticonvulsants | 1 | 2019 | 1881 | 0.330 |
Why?
|
Male | 39 | 2024 | 354908 | 0.330 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2011 | 221 | 0.330 |
Why?
|
Wilms Tumor | 1 | 2011 | 374 | 0.320 |
Why?
|
Brain Ischemia | 1 | 2022 | 3127 | 0.320 |
Why?
|
Ribs | 2 | 2021 | 245 | 0.320 |
Why?
|
Prednisone | 2 | 2011 | 1563 | 0.320 |
Why?
|
Aneurysm, False | 1 | 2011 | 259 | 0.310 |
Why?
|
Executive Function | 1 | 2017 | 1351 | 0.310 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 694 | 0.300 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2011 | 548 | 0.290 |
Why?
|
Stroke | 2 | 2022 | 9879 | 0.290 |
Why?
|
von Willebrand Factor | 3 | 2016 | 672 | 0.280 |
Why?
|
Lymphoma, Follicular | 1 | 2011 | 450 | 0.280 |
Why?
|
Genetic Association Studies | 1 | 2016 | 2711 | 0.270 |
Why?
|
Pelvis | 1 | 2011 | 736 | 0.270 |
Why?
|
Female | 33 | 2024 | 386085 | 0.270 |
Why?
|
Blood Coagulation Tests | 2 | 2017 | 267 | 0.260 |
Why?
|
Mutation | 5 | 2023 | 29706 | 0.250 |
Why?
|
Risk Factors | 15 | 2024 | 73425 | 0.230 |
Why?
|
Drug Dosage Calculations | 2 | 2021 | 116 | 0.220 |
Why?
|
Quality of Life | 2 | 2016 | 13154 | 0.220 |
Why?
|
Adult | 19 | 2023 | 216927 | 0.220 |
Why?
|
Body Mass Index | 1 | 2021 | 12796 | 0.220 |
Why?
|
Neoplasms, Second Primary | 1 | 2011 | 1051 | 0.210 |
Why?
|
Cognition Disorders | 1 | 2017 | 3970 | 0.210 |
Why?
|
Retrospective Studies | 14 | 2022 | 79133 | 0.200 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2017 | 5551 | 0.200 |
Why?
|
Embolization, Therapeutic | 1 | 2011 | 1394 | 0.190 |
Why?
|
Hospitalization | 1 | 2020 | 10629 | 0.180 |
Why?
|
Phenotype | 4 | 2023 | 16443 | 0.180 |
Why?
|
Follow-Up Studies | 5 | 2021 | 39077 | 0.180 |
Why?
|
Glucocorticoids | 1 | 2010 | 2146 | 0.180 |
Why?
|
Severity of Illness Index | 3 | 2021 | 15680 | 0.180 |
Why?
|
Antithrombins | 1 | 2023 | 311 | 0.170 |
Why?
|
Acute Generalized Exanthematous Pustulosis | 1 | 2009 | 14 | 0.170 |
Why?
|
Amoxicillin-Potassium Clavulanate Combination | 1 | 2009 | 34 | 0.170 |
Why?
|
Exercise | 1 | 2016 | 5746 | 0.170 |
Why?
|
Half-Life | 2 | 2019 | 648 | 0.160 |
Why?
|
Obesity | 1 | 2021 | 12806 | 0.160 |
Why?
|
Cohort Studies | 5 | 2021 | 40980 | 0.150 |
Why?
|
Cellulitis | 1 | 2009 | 207 | 0.150 |
Why?
|
Phlebography | 1 | 2018 | 325 | 0.150 |
Why?
|
Genotype | 3 | 2018 | 12869 | 0.140 |
Why?
|
Ultrasonography, Doppler | 1 | 2018 | 463 | 0.140 |
Why?
|
Drug Eruptions | 1 | 2009 | 329 | 0.140 |
Why?
|
Hemarthrosis | 1 | 2016 | 38 | 0.130 |
Why?
|
Skin Neoplasms | 2 | 2014 | 5726 | 0.130 |
Why?
|
Systemic Inflammatory Response Syndrome | 1 | 2021 | 616 | 0.130 |
Why?
|
Diagnosis, Differential | 3 | 2018 | 12901 | 0.130 |
Why?
|
Edetic Acid | 1 | 2016 | 280 | 0.130 |
Why?
|
Patient Readmission | 1 | 2010 | 3288 | 0.130 |
Why?
|
Prognosis | 3 | 2021 | 29337 | 0.130 |
Why?
|
Kidney Neoplasms | 1 | 2011 | 4275 | 0.120 |
Why?
|
Nail Diseases | 1 | 2014 | 51 | 0.120 |
Why?
|
Pilot Projects | 2 | 2018 | 8443 | 0.120 |
Why?
|
Thrombelastography | 1 | 2016 | 173 | 0.110 |
Why?
|
Platelet Count | 1 | 2016 | 774 | 0.110 |
Why?
|
Urogenital Neoplasms | 1 | 2014 | 135 | 0.110 |
Why?
|
Cross-Sectional Studies | 3 | 2021 | 25539 | 0.110 |
Why?
|
Genes, X-Linked | 1 | 2013 | 128 | 0.110 |
Why?
|
Eye Neoplasms | 1 | 2014 | 307 | 0.100 |
Why?
|
Immunoassay | 1 | 2016 | 746 | 0.100 |
Why?
|
Survival Rate | 2 | 2020 | 12745 | 0.100 |
Why?
|
Inpatients | 1 | 2024 | 2562 | 0.100 |
Why?
|
Treatment Outcome | 7 | 2021 | 64250 | 0.100 |
Why?
|
Mucous Membrane | 1 | 2014 | 654 | 0.100 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2012 | 11587 | 0.090 |
Why?
|
Leukemia, Biphenotypic, Acute | 1 | 2010 | 32 | 0.090 |
Why?
|
Vascular Surgical Procedures | 1 | 2019 | 1458 | 0.090 |
Why?
|
Prevalence | 2 | 2018 | 15508 | 0.090 |
Why?
|
Leukemia, T-Cell | 1 | 2010 | 101 | 0.090 |
Why?
|
Genes, Recessive | 1 | 2013 | 626 | 0.090 |
Why?
|
Structure-Activity Relationship | 1 | 2016 | 3078 | 0.090 |
Why?
|
Genes, Dominant | 1 | 2013 | 865 | 0.090 |
Why?
|
Binding Sites | 1 | 2019 | 6028 | 0.090 |
Why?
|
Enzyme Activation | 1 | 2016 | 3597 | 0.090 |
Why?
|
Family | 1 | 2021 | 3166 | 0.090 |
Why?
|
Furans | 1 | 2011 | 193 | 0.090 |
Why?
|
Prospective Studies | 3 | 2023 | 53809 | 0.080 |
Why?
|
Hospitals | 1 | 2022 | 3915 | 0.080 |
Why?
|
Diagnostic Errors | 1 | 2016 | 1246 | 0.080 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 2010 | 534 | 0.080 |
Why?
|
Vincristine | 1 | 2011 | 1028 | 0.080 |
Why?
|
Remission Induction | 2 | 2011 | 2368 | 0.080 |
Why?
|
Hospitals, Pediatric | 1 | 2017 | 1830 | 0.080 |
Why?
|
Jugular Veins | 1 | 2009 | 211 | 0.080 |
Why?
|
Protein Conformation | 1 | 2016 | 3956 | 0.080 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2011 | 2495 | 0.080 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2011 | 695 | 0.070 |
Why?
|
Exons | 1 | 2013 | 2383 | 0.070 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2014 | 950 | 0.070 |
Why?
|
Thiophenes | 1 | 2011 | 586 | 0.070 |
Why?
|
Incidence | 3 | 2022 | 21157 | 0.070 |
Why?
|
Logistic Models | 2 | 2018 | 13277 | 0.070 |
Why?
|
Pedigree | 1 | 2014 | 4573 | 0.070 |
Why?
|
Calcium | 1 | 2019 | 5699 | 0.070 |
Why?
|
Models, Molecular | 1 | 2016 | 5385 | 0.070 |
Why?
|
Case-Control Studies | 2 | 2021 | 21851 | 0.070 |
Why?
|
Magnetic Resonance Imaging | 3 | 2019 | 35932 | 0.070 |
Why?
|
Recurrence | 1 | 2018 | 8420 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2022 | 10196 | 0.060 |
Why?
|
DNA Mutational Analysis | 1 | 2014 | 4110 | 0.060 |
Why?
|
Cyclophosphamide | 1 | 2011 | 2194 | 0.060 |
Why?
|
Cell Separation | 1 | 2011 | 1719 | 0.060 |
Why?
|
Transplantation Conditioning | 1 | 2012 | 1555 | 0.060 |
Why?
|
Hodgkin Disease | 1 | 2012 | 1377 | 0.060 |
Why?
|
Doxorubicin | 1 | 2011 | 2192 | 0.060 |
Why?
|
Mutation, Missense | 1 | 2013 | 2556 | 0.060 |
Why?
|
Physicians | 1 | 2022 | 4551 | 0.060 |
Why?
|
Base Sequence | 1 | 2014 | 12432 | 0.060 |
Why?
|
Age Factors | 2 | 2021 | 18298 | 0.060 |
Why?
|
Genetic Predisposition to Disease | 2 | 2014 | 17647 | 0.050 |
Why?
|
Pandemics | 1 | 2022 | 8511 | 0.050 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2010 | 1572 | 0.050 |
Why?
|
Homeodomain Proteins | 1 | 2010 | 2408 | 0.050 |
Why?
|
Survival Analysis | 1 | 2014 | 10172 | 0.050 |
Why?
|
Anti-Bacterial Agents | 1 | 2009 | 7295 | 0.050 |
Why?
|
Embolectomy | 1 | 2021 | 128 | 0.050 |
Why?
|
Tumor Suppressor Proteins | 1 | 2010 | 2796 | 0.040 |
Why?
|
Head and Neck Neoplasms | 1 | 2014 | 2868 | 0.040 |
Why?
|
Flow Cytometry | 1 | 2011 | 5838 | 0.040 |
Why?
|
Repressor Proteins | 1 | 2010 | 2973 | 0.040 |
Why?
|
Postoperative Complications | 1 | 2022 | 15438 | 0.040 |
Why?
|
Cognition | 1 | 2017 | 6849 | 0.040 |
Why?
|
Prothrombin Time | 1 | 2019 | 116 | 0.040 |
Why?
|
Graft vs Host Disease | 1 | 2012 | 2964 | 0.040 |
Why?
|
Radiology, Interventional | 1 | 2022 | 470 | 0.040 |
Why?
|
North America | 1 | 2022 | 1279 | 0.040 |
Why?
|
Depression | 1 | 2017 | 7921 | 0.040 |
Why?
|
Melanoma | 1 | 2014 | 5620 | 0.030 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2010 | 3589 | 0.030 |
Why?
|
Neutropenia | 1 | 2019 | 882 | 0.030 |
Why?
|
Consensus | 1 | 2022 | 3034 | 0.030 |
Why?
|
Antineoplastic Agents | 2 | 2012 | 13550 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2019 | 4876 | 0.020 |
Why?
|
Intensive Care Units, Neonatal | 1 | 2018 | 824 | 0.020 |
Why?
|
Bacteremia | 1 | 2018 | 977 | 0.020 |
Why?
|
Acute Disease | 1 | 2021 | 7212 | 0.020 |
Why?
|
Anemia | 1 | 2019 | 1495 | 0.020 |
Why?
|
United States | 1 | 2018 | 71438 | 0.020 |
Why?
|
Chromosomes, Human, Pair 22 | 1 | 2010 | 342 | 0.020 |
Why?
|
Combined Modality Therapy | 2 | 2012 | 8539 | 0.020 |
Why?
|
Gestational Age | 1 | 2018 | 3545 | 0.020 |
Why?
|
Hematologic Diseases | 1 | 2012 | 494 | 0.020 |
Why?
|
Catheters, Indwelling | 1 | 2009 | 426 | 0.020 |
Why?
|
Middle Aged | 1 | 2021 | 217039 | 0.020 |
Why?
|
Sequence Deletion | 1 | 2010 | 1494 | 0.020 |
Why?
|
Translocation, Genetic | 1 | 2010 | 1369 | 0.020 |
Why?
|
Length of Stay | 1 | 2018 | 6372 | 0.010 |
Why?
|
Sex Factors | 1 | 2018 | 10457 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 4571 | 0.010 |
Why?
|
Bone Marrow Transplantation | 1 | 2010 | 2661 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2012 | 6780 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2012 | 6501 | 0.010 |
Why?
|
Risk Assessment | 1 | 2022 | 23788 | 0.010 |
Why?
|
Ultrasonography | 1 | 2009 | 5919 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2010 | 12739 | 0.010 |
Why?
|